T cells specific for such TMAs function, however, only in very immunocompromised microenvironments, which may explain why ARG1- or TGFβ-targeting therapeutic vaccines can activate specific immunity in animal models of cancer without causing associated side effects or systemic toxicity [87, 104]. Here, ARG1 is linked to cancer.